论文部分内容阅读
自1976年使用消炎痛治疗动脉导管未闭以来,关于其有效性和副作用的报告很多。1983年美国的一项研究指出,使用一般疗法不能使导管闭锁的情况下, 应用消炎痛是妥当的。但关于给药剂量、时机、疗程等问题仍悬而未决。 1987年Krueger等提出,对出生体重750～1500g的呼吸窘迫症候群的未熟儿,于生后24小时内给予消炎痛,对预防症状性动脉导管未闭(PDA)的发生是有效的,因此认为,早期应用消炎痛预防PDA是妥当的。对此,Clyman等提出了相反的意见,认为早期
Since indomethacin was used to treat patent ductus arteriosus in 1976, there have been a number of reports about its efficacy and side effects. A 1983 study in the United States pointed out that the use of indomethacin is appropriate when general therapies do not block the catheter. However, the dosage, timing, treatment and other issues are still pending. In 1987, Krueger et al. Proposed that indomethacin should be given within 24 hours after birth to infants who have a respiratory distress syndrome with a birth weight of 750-1500g. This is effective in preventing the development of symptomatic patent ductus arteriosus (PDA) Early application of indomethacin to prevent PDA is appropriate. In this regard, Clyman et al. Put forward the opposite opinion, that early